top of page

Nanoencapsulation of

Poorly Soluble Drugs

Using its library of patented polymers, ANP has successfully nanoencapsulated poorly soluble drugs to improve their pharmacokinetics, reduce their toxicity, and enhance their therapeutic efficacy.


By enclosing poorly soluble drugs within a capsule of self-assembled polymeric molecules, the resultant amorphous drug(s) become readily water soluble, thus greatly enhancing their bioavailability. Based on our extensive experience with many poorly soluble drugs, we can structurally fine-tune our polymers for maximum efficacy of each insoluble drug’s therapeutic performance. Our nanoencapsulation technology is ideal for formulating poorly soluble drugs into soluble surfactant- and solvent-free amorphous drug entities for IV injection.

  • Increased solubility of poorly soluble small molecules, greatly enhancing their bioavailability as well as administration flexibility (IV, Oral, etc.)

  • Enhanced tissue penetration leading to greater overall efficacy, pharmacokinetics, and reduced toxicity.

Our Lab Studies

Paclitaxel is a known, poorly soluble drug. Through nanoencapsulation, we have made the nanoencapsulated paclitaxel (FID-007) soluble in water for IV injection.  Efficacy studies using FID-007 have shown tumor reduction in breast, ovarian, lung, leukemia, pancreatic, gastric and bladder cancers in a mouse xenograft model.

AAPS poster: "Comparison of In Vivo Efficacy of Nanoencapsulated Paclitaxel with Taxol and Abraxane, AAPS National Meeting, November 11, 2013"

bottom of page